| Name | Chlorpropamide |
| Description | Chlorpropamide (Diabinese) is a sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. |
| Kinase Assay | Androgen Receptor Assay: Aliquots of 100 μl cytosol are incubated at 0-4°C for 18 h with 100 μl of the indicated saturating concentration of [3H]T in the presence or absence of increasing concentrations of nonlabeled T, DHT, flutamide (FLU) or flutamide-OH (FLU-OH). At the end of the incubation, free and bound T are separated by the addition of 200 μl dextran-coated charcoal (1 % charcoal, 0.1% dextran T-70, 0.1% gelatin, 1.5 mM EDTA and 50 mM Tris (pH 7.4)) for 15 min before centrifugation at 2300 × g for another 15 min at 0-4°C. Aliquots (350 μl) of the supernatant are transferred to scintillation vials with 10 ml of an aqueous counting solution before counting in a Beckman LS 330 counter. |
| In vivo | At a concentration of 0.2 mM, chlorpropamide elevated the levels of fructose-2,6-bisphosphate (F-2,6-P2) in isolated hepatocytes from rats. The compound operates through a cyclic AMP-independent mechanism, enhancing insulin's inhibitory effect on glucagon-stimulated gluconeogenesis. Chlorpropamide significantly increased glucose metabolism and total lipid content, irrespective of insulin deficiency (30%) or presence (31%). |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.23 mM), Sonication is recommended.
Ethanol : 51 mg/mL (184.29 mM), Sonication is recommended.
DMSO : 55 mg/mL (198.74 mM), Sonication is recommended.
|
| Keywords | Sodium potassium pump | Na+/K+ ATPase | Inhibitor | inhibit | Chlorpropamide | ABCC8 |
| Inhibitors Related | Sodium oleate | Permethrin | Tolbutamide | Vismodegib | Vigabatrin | trans-Aconitic acid | Phlorizin | 2,3-Butanedione 2-Monoxime | Probucol | Revaprazan hydrochloride | Oleic acid | Acridone |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Membrane Protein-targeted Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Anti-Diabetic Compound Library | ReFRAME Related Library | Toxic Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library | Anti-Metabolism Disease Compound Library | Anti-Cancer Drug Library |
United States
